Gabelli Funds LLC Takes Position in Drugs Made In America Acquisition II Corp. $DMII

Gabelli Funds LLC purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 161,400 shares of the company’s stock, valued at approximately $1,609,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new position in Drugs Made In America Acquisition II in the 4th quarter worth $265,000. Virtu Financial LLC purchased a new position in Drugs Made In America Acquisition II in the 4th quarter valued at about $317,000. ABC Arbitrage SA acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at about $396,000. Deltec Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at about $495,000. Finally, Royal Bank of Canada purchased a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth about $655,000.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

DMII opened at $10.12 on Thursday. The company has a fifty day moving average of $10.08. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.20.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.